|
1
|
Cai H and Harrison DG: Endothelial
dysfunction in cardiovascular diseases: The role of oxidant stress.
Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Nunzio C, Aronson W, Freedland SJ,
Giovannucci E and Parsons JK: The correlation between metabolic
syndrome and prostatic diseases. Eur Urol. 61:560–570. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sychlowy A, van der Gaag H and
Hannen-Hofheinz I: Hyperkalemia-life-threatening early complication
of asphyxia in premature infants. Monatsschr Kinderheilkd.
138:62–65. 1990.(In German). PubMed/NCBI
|
|
4
|
Saito M, Tsounapi P, Oikawa R, Shimizu S,
Honda M, Sejima T, Kinoshita Y and Tomita S: Prostatic ischemia
induces ventral prostatic hyperplasia in the SHR; possible
mechanism of development of BPH. Sci Rep. 4:38222014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shim V, Gauthier ML, Sudilovsky D, Mantei
K, Chew KL, Moore DH, Cha I, Tlsty TD and Esserman LJ:
Cyclooxygenase-2 expression is related to nuclear grade in ductal
carcinoma in situ and is increased in its normal adjacent
epithelium. Cancer Res. 63:2347–2350. 2003.PubMed/NCBI
|
|
6
|
Miyake H, Hara I, Kamidono S and Eto H:
Oxidative DNA damage in patients with prostate cancer and its
response to treatment. J Urol. 171:1533–1536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nelson WG, DeWeese TL and DeMarzo AM: The
diet, prostate inflammation, and the development of prostate
cancer. Cancer Metastasis Rev. 21:3–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanwal R, Pandey M, Bhaskaran N, Maclennan
GT, Fu P, Ponsky LE and Gupta S: Protection against oxidative DNA
damage and stress in human prostate by glutathione S-transferase
P1. Mol Carcinog. 53:8–18. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koul HK, Kumar B, Koul S, Deb AA, Hwa JS,
Maroni P, van Bokhoven A, Lucia MS, Kim FJ and Meacham RB: The role
of inflammation and infection in prostate cancer: Importance in
prevention, diagnosis and treatment. Drugs Today (Barc).
46:929–943. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu Q and Ni X: ROS-mediated DNA
methylation pattern alterations in carcinogenesis. Curr Drug
Targets. 16:13–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raza Y, Khan A, Farooqui A, Mubarak M,
Facista A, Akhtar SS, Khan S, Kazi JI, Bernstein C and Kazmi SU:
Oxidative DNA damage as a potential early biomarker of Helicobacter
pylori associated carcinogenesis. Pathol Oncol Res. 20:839–846.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukumoto K, Nagai A, Hara R, Fujii T and
Miyaji Y: Tadalafil for male lower urinary tract symptoms improves
endothelial function. Int J Urol. 24:206–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yokoyama O, Ozeki A, Suzuki N and Murakami
M: Early improvement of storage or voiding symptoms by tadalafil
predicts treatment outcomes in patients with lower urinary tract
symptoms from benign prostatic hyperplasia. Int J Urol. 25:240–245.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gotoh D, Torimoto K, Tatsumi Y, Hori S,
Yamada A, Miyake M, Morizawa Y, Aoki K, Tanaka N, Hirayama A, et
al: Tadalafil, a phosphodiesterase type 5 inhibitor, improves
bladder blood supply and restores the initial phase of lower
urinary tract dysfunction in diabetic rats. Neurourol Urodyn.
35:444–449. 2017.
|
|
15
|
Vignozzi L, Gacci M, Cellai I, Morelli A,
Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi
G, et al: PDE5 inhibitors blunt inflammation in human BPH: A
potential mechanism of action for PDE5 inhibitors in LUTS.
Prostate. 73:1391–1402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zarifpour M, Nomiya M, Sawada N and
Andersson KE: Protective effect of tadalafil on the functional and
structural changes of the rat ventral prostate caused by chronic
pelvic ischemia. Prostate. 75:233–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
